Tag Archives: LIMR

Groundbreaking diagnostic test developed at LIMR receives FDA authorization

  For the first time a test that can aid in the detection of an infection in the synovial fluid surrounding a patient’s joint replacement has been authorized by the U.S. Food and Drug Administration (FDA). The Synovasure Alpha Defensin … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment trial for men with localized intermediate-risk prostate cancer

  By Donna Loyle, communications specialist, LIMR   June is Men’s Health Month, which makes this an ideal time to highlight clinical study #NRG GU005, a randomized phase III trial comparing stereotactic body radiation therapy (SBRT) to intensity-modulated radiation therapy … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Speaker to discuss data mining to better characterize genes

  “Data Mining in the Post-Genomic Era,” is the topic of the next seminar hosted by the Lankenau Institute for Medical Research. The seminar will take place on Thursday, June 20 at 2:00 pm in the McLean Conference Room, Lankenau … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment trial for patients with recurrent, persistent or metastatic endometrial cancer

By Donna Loyle, communications specialist, LIMR Main Line Health researchers seek patients diagnosed with recurrent, persistent or metastatic endometrial cancer for a randomized phase II clinical trial comparing the experimental drug cediranib, the FDA-approved therapy olaparib, and the combination of … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment trial for patients diagnosed with high-risk anal cancer

  By Donna Loyle, communications specialist, LIMR   Main Line Health is participating in a phase II treatment study for patients diagnosed with high-risk anal cancer. Researchers seek to determine if the immunotherapy drug nivolumab (Opdivo®) can help these patients. … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Lupus researcher to speak at LMC

  Laurence Morel, PhD, professor and vice chair for research and academic affairs in the Department of Pathology at University of Florida, will visit Lankenau Institute for Medical Research on Thursday, June 6, to give the talk “Tryptophan metabolism, microbiome … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment study for patients with glioblastoma-related cognitive decline

By Donna Loyle, communications specialist, LIMR Patients diagnosed with glioblastoma and being treated with brain radiotherapy and temozolomide may qualify to participate in a single-arm study that seeks to determine if the oral drug Altace® (ramipril) can reduce the chance … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Expanding the arsenal of available healthcare options, a celebration of clinical trials day

By Donna Loyle, communications specialist, LIMR   May 20 is National Clinical Trials Day, a special time of year to recognize the hard work and achievements of those who conduct clinical research. The date marks a fateful day in 1747 … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Interventional trial for patients diagnosed with calcified lesions of the coronary arteries

  By Donna Loyle, communications specialist, LIMR Researchers seek patients who’ve been diagnosed with calcified lesion(s) of the coronary arteries to participate in the Disrupt CAD III clinical trial. This is a prospective, multicenter, single-arm, global IDE study to evaluate … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment trial for relapsed or refractory follicular lymphoma

  By Donna Loyle, communications specialist, LIMR   Researchers seek to determine the best therapy for patients diagnosed with relapsed or refractory follicular lymphoma. They are testing how well the monoclonal antibody obinutuzumab (Gazyva®) works with other medications.   Inclusion … Continue reading

Posted in Clinician News | Tagged | Leave a comment